SCIMITAR is the first phase 2 trial testing the efficacy of stereotactic body radiation therapy (SBRT) targeting the prostate fossa after radical prostatectomy.

Recent research has put a spotlight on a number of factors which could be used to estimate which patients with nonmetastatic, unfavorable-risk prostate cancer are at high risk for a shorter time until ...

Currently, postoperative prostate-specific antigen (PSA) levels are the preferred noninvasive biomarker in patient follow-ups, but sufficient criteria for predicting biochemical recurrence have not ...

SAN ANTONIO -- More than 2 years after treatment, no patient with high-risk prostate cancer had a confirmed biochemical recurrence after receiving postoperative apalutamide (Erleada) and androgen ...

Adding apalutamide to androgen deprivation therapy prolonged prostate-specific antigen progression-free survival in patients with biochemically recurrent prostate cancer in the phase 3 PRESTO trial.

The recurrence of prostate cancer can now be detected 14.8 months sooner than existing clinical practices with new technology developed by a professor at Purdue University in West Lafayette, Ind. The ...

A 1-year period of intensified androgen receptor blockade prolonged prostate-specific antigen progression-free survival (PSA-PFS) compared with androgen deprivation therapy (ADT) alone for patients ...

Prostate-specific antigen (PSA) defined biochemical recurrence (BCR) of prostate cancer is widely used for reporting the outcome of radical prostatectomy (RP). A standardized BCR definition is lacking ...

− Post-hoc analysis from Blue Earth Diagnostics’ Phase 3 SPOTLIGHT trial provides data about treatment planning, particularly when curative salvage therapy is considered – MONROE TOWNSHIP, N.J. & ...

Treatments intended to reduce biochemical recurrence in patients with prostate cancer may not improve long-term survival, recent research showed. Certain prostate cancer treatments used to reduce the ...